Study summary · research use only
Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This perspective article (species not specified; human clinical context) discusses using Cerebrolysin as an adjunct to reperfusion therapy in acute ischemic stroke (AIS). The authors describe Cerebrolysin's reported effects on neurorecovery, the neurovascular unit, and the blood-brain barrier, and introduce the CErebrolysin in RECanalization And Perfusion (CERECAP) program, a collaborative initiative of independent academic investigations examining trends in Cerebrolysin use alongside reperfusion. The article reviews these studies and discusses the need to define which patient populations may derive the most benefit from adjunctive Cerebrolysin therapy in AIS, without presenting new trial data of its own.
Abstract
This article provides perspectives on the use of Cerebrolysin as an adjunct treatment to reperfusion therapy in acute ischemic stroke (AIS). In the evolving landscape of AIS reperfusion therapy, we hypothesize that adjunctive cerebroprotective therapy, such as Cerebrolysin, is likely to further improve patient outcomes. Beyond its established neurorecovery benefits, recent data indicate that Cerebrolysin also offers protection to the neurovascular unit and the blood-brain barrier. This paper introduces the CErebrolysin in RECanalization And Perfusion (CERECAP) program, a collaborative initiative of independent academic investigations exploring the favorable trends of Cerebrolysin in reperfusion. The CERECAP program has generated compelling data demonstrating Cerebrolysin's alignment with current AIS reperfusion therapy concepts, particularly its role in early intervention targeting multiple pathways. We review these studies and discuss the critical need to clearly define the patient population that benefit most from adjunctive Cerebrolysin therapy in AIS.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.